Subclinical hypothyroidism occurs when your thyroid gland produces enough hormone to keep levels in the normal range, but your brain has to work harder to make that happen. The result is an elevated TSH (the signal your brain sends to stimulate the thyroid) while free T4 and T3, the actual thyroid hormones, remain normal. A TSH above roughly 4.5 mIU/L with normal hormone levels, confirmed over three to six months, is the standard diagnostic threshold. The causes range from autoimmune disease to medications to something as simple as gaining weight.
Hashimoto’s Thyroiditis
The most common cause of subclinical hypothyroidism in areas with adequate iodine intake is Hashimoto’s thyroiditis, a condition in which the immune system attacks the thyroid gland. White blood cells gradually infiltrate the thyroid tissue, and the body produces antibodies against a key enzyme the thyroid needs to make hormones. Over 90% of people with autoimmune thyroiditis test positive for these antibodies. The damage accumulates slowly, which is why many people spend years in a subclinical state before their thyroid output drops enough to cause overt hypothyroidism, if it ever does.
Genetics play a significant role in who develops Hashimoto’s. Studies estimate that about 65% of the variation in TSH levels across a population is genetically determined. Several specific gene variants have been identified that shift a person’s TSH set point up or down, each by small amounts. Family history of any autoimmune thyroid disease, whether Hashimoto’s or Graves’ disease, increases your risk substantially.
Radioactive Iodine and Thyroid Surgery
Treatments for an overactive thyroid frequently lead to an underactive one. Radioactive iodine therapy, commonly used for Graves’ disease and toxic thyroid nodules, destroys enough thyroid tissue to bring hormone levels down, but calibrating the dose precisely is difficult. In people treated for Graves’ disease, about 38.5% develop hypothyroidism, typically within the first 12 months. For those treated for toxic nodular goiters, the rate is lower (around 24%) but the timeline is longer. Some patients continue developing hypothyroidism up to nine years after treatment.
Partial thyroid surgery carries a similar risk. Removing part of the gland reduces its hormone-producing capacity, and whether the remaining tissue can compensate depends on how much was removed and whether the remaining tissue is healthy. Many of these cases initially present as subclinical hypothyroidism before either stabilizing or progressing.
Medications That Affect the Thyroid
Several widely used medications can push TSH levels up. Lithium, prescribed for bipolar disorder, concentrates in the thyroid and interferes with hormone production and release. Amiodarone, a heart rhythm medication, contains large amounts of iodine and can disrupt thyroid function in either direction.
A newer category of concern involves cancer drugs called tyrosine kinase inhibitors. These medications, used to treat kidney cancer, liver cancer, and other malignancies, can damage the thyroid through multiple mechanisms: triggering inflammation in the gland, reducing its blood supply, blocking iodine uptake, and stimulating the production of antibodies against thyroid enzymes. The rates of hypothyroidism with these drugs are striking. Sunitinib causes thyroid underfunction in 53 to 85% of patients. Vandetanib and axitinib cause it in roughly 83 to 92%. If you’re starting any of these medications, expect your thyroid function to be monitored regularly.
Iodine: Too Little or Too Much
Your thyroid needs iodine to build its hormones, and the relationship between iodine intake and thyroid health follows a U-shaped curve. Too little iodine starves the gland of its raw material, forcing TSH higher. But too much iodine can also suppress thyroid function through a protective mechanism that, in some people, doesn’t switch off properly. The recommended daily iodine intake for most adults is about 150 micrograms.
Population-level data from Denmark showed that after the country introduced iodine fortification of salt, the incidence of hypothyroidism actually increased. This doesn’t mean iodine fortification is harmful overall, but it illustrates that shifting a population’s iodine intake in either direction can trigger thyroid dysfunction in susceptible individuals. People with underlying autoimmune thyroiditis are particularly vulnerable to iodine excess.
Thyroiditis That Resolves on Its Own
Not all subclinical hypothyroidism is permanent. Subacute thyroiditis (often triggered by a viral infection), silent thyroiditis, and postpartum thyroiditis all follow a predictable three-phase pattern. First, inflammation damages thyroid cells and dumps stored hormone into the bloodstream, causing a brief period of excess thyroid hormone lasting one to three months. Then the depleted gland enters a hypothyroid phase that can last up to six months. Most people eventually return to normal function.
Postpartum thyroiditis affects roughly 5 to 10% of women, typically appearing two to six months after delivery. The hypothyroid phase is when most women notice symptoms like fatigue, brain fog, and low mood, which are easy to attribute to the demands of a newborn. While most cases resolve, women who experience postpartum thyroiditis have a higher lifetime risk of developing permanent hypothyroidism later.
Obesity and TSH
Excess body fat can raise TSH levels independently of any thyroid disease. Fat cells produce leptin, a hormone that directly stimulates the brain to release more TSH. In people with significant obesity, leptin levels are chronically elevated, which pushes TSH upward even though the thyroid gland itself is healthy. A feedback loop makes this worse: TSH stimulates fat cells to produce even more leptin.
This creates a diagnostic challenge. A mildly elevated TSH in someone with obesity may reflect true thyroid underfunction, or it may simply be a consequence of excess fat tissue signaling the brain. One clue: the elevated TSH and thyroid hormone changes associated with obesity are often reversible with weight loss. If your TSH is only mildly elevated and you carry significant excess weight, this distinction matters because it may change whether treatment with thyroid medication makes sense.
Why Age Changes the Picture
TSH naturally drifts upward as you get older. After age 40, the upper limit of the normal TSH range increases by roughly 0.3 mIU/L for every decade. By age 70 or 80, a TSH of 5 or even 6 mIU/L may fall within the normal range for that age group rather than representing true thyroid failure. Studies across multiple populations consistently show this upward shift.
This means that applying the standard 4.5 mIU/L cutoff to an 80-year-old could lead to a false diagnosis of subclinical hypothyroidism and unnecessary treatment. Many endocrinologists now use age-adjusted reference ranges when evaluating older adults, and clinical trials in people over 65 have generally failed to show benefit from treating mildly elevated TSH. For older adults, a slightly higher TSH is often a normal feature of aging rather than a problem to fix.
When Subclinical Becomes Overt
Subclinical hypothyroidism progresses to full hypothyroidism at a rate of roughly 2 to 5% per year, depending on the cause. The strongest predictor of progression is the presence of thyroid antibodies. If your TSH is elevated and you test positive for anti-thyroid peroxidase antibodies, you are significantly more likely to eventually need treatment than someone with the same TSH but no antibodies. Higher starting TSH values also predict faster progression: someone with a TSH of 8 or 10 is more likely to progress than someone at 5.
On the other hand, many cases of subclinical hypothyroidism remain stable for years or even normalize without treatment. Up to a third of people with mildly elevated TSH will have normal levels on repeat testing, which is why guidelines recommend confirming the diagnosis over three to six months before making treatment decisions.